SCHEMBL6858495

SCHEMBL6858495

CCCCC(=O)Oc1cccc(OCCn2c(C)nc3ccccc3c2=O)c1Br

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EIF4EBP1 Q13541 2/20 0.49
TSHR P16473 2/20 0.48
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTR1A P08908 1/20 0.45
HTR7 P34969 1/20 0.45
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 3/20 0.44
ACKR3 P25106 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
GFER P55789 1/20 0.43
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7013161 0.89 EIF4EBP1 (0.48) EIF4EBP1TSHRGAAL3MBTL1HTR1A
SCHEMBL6858494 0.85 EIF4EBP1 (0.49) EIF4EBP1TSHRGAAHTR1AHTR7
SCHEMBL6858499 0.80 EIF4EBP1 (0.49) EIF4EBP1TSHRHTR1AHTR7MAPT
SCHEMBL6555761 0.77 EIF4EBP1 (0.52) EIF4EBP1TSHRGAAHTR1AHTR7
SCHEMBL6555789 0.77 EIF4EBP1 (0.50) EIF4EBP1TSHRHTR1AHTR7MAPT
SCHEMBL7797529 0.74 EIF4EBP1 (0.49) EIF4EBP1TSHRGAAHTR1AHTR7
SCHEMBL5804256 0.72 UBE2N (0.52) EIF4EBP1TSHRGAAL3MBTL1MAPT
SCHEMBL10526480 0.72 TSHR (0.74) TSHRGAAL3MBTL1HTR1AHTR7
SCHEMBL12963486 0.70 MEN1 (0.73) TSHRGAAL3MBTL1HTR1AHTR7
SCHEMBL3829770 0.70 TSHR (0.64) EIF4EBP1TSHRGAAL3MBTL1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780992-B2 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL) -ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONE FOR EXAMPLE; ALSO OXAZOLIDINE-2,4-DIONE, AND 1,2,4-OXADIAZOLIDINE-3,5-DIONE DERIVATIVES; REDUCING BLOOD GLUCOSE LEVELS DR. REDDY'S LABORATORIES LTD. (IN) 2004-08-24 US disclosed
US-20020123502-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. 2002-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123502-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases IAPP, GPR119, CYP11B1 EIF4EBP1 2618/4885TSHR 2630/4885GAA 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.